Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Ursogal 150mg tablets
0109010U0BDAAAA
|
Ursogal | Ursodeoxycholic acid | Gastro-Intestinal System | No data available |
|
Ursogal 250mg capsules
0109010U0BDABAB
|
Ursogal | Ursodeoxycholic acid | Gastro-Intestinal System | No data available |
|
Ustekinumab 130mg/26ml solution for infusion vials
0105030B0AAAAAA
|
Ustekinumab | Ustekinumab | Gastro-Intestinal System | No data available |
|
Ustekinumab 45mg/0.5ml inj pre-filled syringes
1305030D0AAABAB
|
Ustekinumab | Ustekinumab | Skin | No data available |
|
Ustekinumab 45mg/0.5ml solution for injection vials
1305030D0AAAAAA
|
Ustekinumab | Ustekinumab | Skin | No data available |
|
Utinor 400mg tablets
0501120Q0BBAAAA
|
Utinor | Norfloxacin | Infections | No data available |
|
Uvesterol D 1,500units/ml oral solution
0906040N0CBAAFM
|
Uvesterol D | Ergocalciferol | Nutrition and Blood | No data available |
|
Uvistat children's sun cream SPF 20
130801000BBKPA0
|
Proprietary compound preparation BNF 1308010 | Other sunscreening preparations | Skin | No data available |
|
Uvistat children's sun cream SPF 30
130801000BBKQA0
|
Proprietary compound preparation BNF 1308010 | Other sunscreening preparations | Skin | No data available |
|
Uvistat lipscreen SPF 30
130801000BBHHA0
|
Proprietary compound preparation BNF 1308010 | Other sunscreening preparations | Skin | No data available |
|
Uvistat long lasting waterproof sun cream SPF 25
130801000BBAUA0
|
Proprietary compound preparation BNF 1308010 | Other sunscreening preparations | Skin | No data available |
|
Uvistat sun cream SPF 15
130801000BBALA0
|
Proprietary compound preparation BNF 1308010 | Other sunscreening preparations | Skin | No data available |
|
Uvistat sun cream SPF 20
130801000BBNRA0
|
Proprietary compound preparation BNF 1308010 | Other sunscreening preparations | Skin | No data available |
|
Uvistat Sunblock cream SPF 20
130801000BBAMA0
|
Proprietary compound preparation BNF 1308010 | Other sunscreening preparations | Skin | No data available |
|
Uvistat Ultrablock cream SPF 30
130801000BBANA0
|
Proprietary compound preparation BNF 1308010 | Other sunscreening preparations | Skin | No data available |
|
Uxil 110.6mg tablets
0801050ANBCAEAL
|
Uxil | Dasatinib | Malignant Disease and Immunosuppression | No data available |
|
Uxil 15.8mg tablets
0801050ANBCAAAH
|
Uxil | Dasatinib | Malignant Disease and Immunosuppression | No data available |
|
Uxil 39.5mg tablets
0801050ANBCABAI
|
Uxil | Dasatinib | Malignant Disease and Immunosuppression | No data available |
|
Uxil 63.2mg tablets
0801050ANBCACAJ
|
Uxil | Dasatinib | Malignant Disease and Immunosuppression | No data available |
|
Uxil 79.0mg tablets
0801050ANBCADAK
|
Uxil | Dasatinib | Malignant Disease and Immunosuppression | No data available |
|
Uzpruvo 130mg/26ml concentrate for solution for inf vials
0105030B0BFAAAA
|
Uzpruvo | Ustekinumab | Gastro-Intestinal System | No data available |
|
Uzpruvo 45mg/0.5ml inj pre-filled syringes
1305030D0BDAAAB
|
Uzpruvo | Ustekinumab | Skin | No data available |
|
Uzpruvo 90mg/1ml solution for injection pre-filled syringes
1305030D0BDABAC
|
Uzpruvo | Ustekinumab | Skin | No data available |
|
V.A.C. Via 7-day kit
20032500015
|
V.A.C. Via 7-day kit | Wound Management & Other Dressings | Dressings | No data available |
|
V.A.C. Via canister kit
20032200009
|
V.A.C. Via canister kit | Wound Management & Other Dressings | Dressings | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.